Summary

Healthy Volunteers
healthy people welcome
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Benjamin B. Bert, MD (ucla)

Description

Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Details

To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.

Keywords

Glaucoma Ocular Surface Disease xiidra™ ocular surface discomfort Pharmaceutical Solutions Lifitegrast Ophthalmic Solutions Xiidra (Lifitegrast ophthalmic solution) 5%

Eligibility

You can join if…

  • Currently using one or more topical glaucoma antihypertensives
  • Self-described symptoms of ocular surface discomfort
  • Xiidra is being prescribed as part of the subject's standard care

You CAN'T join if...

  • History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
  • current use of topical cyclosporine
  • current use of topical steroids
  • incisional ocular surgery within 6 months

Location

  • Doheny Eye Center UCLA accepting new patients
    Fountain Valley California 92708 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT04354545
Study Type
Observational
Last Updated